Aim: We aimed to evaluate risk categorization according to the Sydney classification in lymph node aspirations performed in our hospital, which has a large archive.Material and Methods: Three hundred fifteen lymph node fine-needle aspiration (FNAB) smears were reassessed and classified using the Sydney classification.Clinical and histopathological findings were compared.Risk of malignancy (ROM), sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were evaluated.Results: Fine needle aspiration biopsies (FNAB) of a total of 315 cases, 74 (23.5%) men and 241 (76.5%) women, were examined.One hundred sixty-eight of 315 cases had a history of previously diagnosed tumors.In terms of diagnostic categories, 12 (3.8%)cases were L1 (non-diagnostic), 122 (38.7%)L2 (benign), 7 (2.2%)L3 (AUS/ALUS), 27 (8.6%)L4 (suspicion of malignancy), and 147 (46.7%) were in the L5 (malignant) category.Thus, L5 and L2 were the most frequently used categories.There was discordance in the histopathologic examination of 25 (20,5%) cases (mostly Hodgkin's lymphoma) in the L2 (benign) category.The ROM in the L1 category was 58.3%, in the L2 category-20.5%, in the L3 category-57.1%, in the L4 category-92.6%and in the L5 category-100%.The diagnostic performance of lymph node fine-needle aspiration biopsy (FNAB) was evaluated by calculating sensitivity (98,1%), specificity (82,7%), positive predictive value (74,5%), negative predictive value (98,9%), and accuracy (87,9%).Discussion: We believe that the Sydney classification for reporting FNAB improves the quality of the procedure, understanding of the report, and communication between clinicians and cytopathologists, leading to better patient management.